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INTRODUCTION {#bip22773-sec-0001}
============

Although the primary epidemic of severe acute respiratory syndrome (SARS)[1](#bip22773-bib-0001){ref-type="ref"}, [2](#bip22773-bib-0002){ref-type="ref"}, [3](#bip22773-bib-0003){ref-type="ref"} was eventually brought under control, the recent identification of a SARS CoV (coronavirus)‐like virus in Chinese bats[4](#bip22773-bib-0004){ref-type="ref"}, [5](#bip22773-bib-0005){ref-type="ref"} indicates that there are natural reservoirs for this virus. Since no effective therapy exists for these viral infections, developing anti‐SARS agents against future outbreaks remains a formidable challenge. In the early stage of the infection, SARS 3CL protease (3CL^pro^) is a key enzyme to cleave polyproteins to yield functional polypeptides for replication.[6](#bip22773-bib-0006){ref-type="ref"}, [7](#bip22773-bib-0007){ref-type="ref"} The 3CL^pro^ is a cysteine protease containing a Cys‐His catalytic dyad. Because of its functional importance in the viral lifecycle, 3CL^pro^ is considered an attractive target for the structure‐based design of drugs against SARS. Thus, numerous inhibitors of 3CL^pro^ have been reported including peptide‐mimics[8](#bip22773-bib-0008){ref-type="ref"}, [9](#bip22773-bib-0009){ref-type="ref"}, [10](#bip22773-bib-0010){ref-type="ref"}, [11](#bip22773-bib-0011){ref-type="ref"}, [12](#bip22773-bib-0012){ref-type="ref"} and small molecules derived from natural products,[13](#bip22773-bib-0013){ref-type="ref"}, [14](#bip22773-bib-0014){ref-type="ref"}, [15](#bip22773-bib-0015){ref-type="ref"} anti‐viral agents,[16](#bip22773-bib-0016){ref-type="ref"}, [17](#bip22773-bib-0017){ref-type="ref"} anti‐malaria agents,[18](#bip22773-bib-0018){ref-type="ref"} or high throughput screening.[19](#bip22773-bib-0019){ref-type="ref"}, [20](#bip22773-bib-0020){ref-type="ref"}, [21](#bip22773-bib-0021){ref-type="ref"}, [22](#bip22773-bib-0022){ref-type="ref"}

In the course of our own studies on SARS 3CL^pro^ and its inhibitors,[23](#bip22773-bib-0023){ref-type="ref"} we found that mature SARS 3CL^pro^ is sensitive to degradation at the 188Arg/189Gln site, and the Arg188Ile mutant is resistant to this degradation. As a result, this stable mutant protease makes it feasible for evaluating designed and synthesized inhibitors. Exploring useful inhibitors for SARS 3CL^pro^ based on the substrate revealed that peptide aldehyde is a facile for designing an inhibitor for SARS 3CL^pro^. Through combinations of the systematic substitution of peptide aldehyde amino acid and the crystallographic analysis of the complexes, a leading inhibitor (Table [1](#bip22773-tbl-0001){ref-type="table"}, entry **1**) emerged. This peptide‐based inhibitor has all of its side‐chain structures differing from the substrate non‐prime site sequence, Thr‐Ser‐Ala‐Val‐Leu‐Gln, except at the P~3~ site where the side‐chain was directed outward. Especially, substitution of Leu to cyclohexyl alanine (Cha) P~2~ of the peptide inhibitor gave a higher increase in inhibitory potency to SARS 3CL^pro^ (Table [1](#bip22773-tbl-0001){ref-type="table"}, entries **1** and **2**). Moreover, crystallographic analysis of the inhibitor complex provided an extended design of both deletion at the P~5~ residue and mutation providing a hetero atom at the P~4~ position of the inhibitor. Evaluation of IC~50~ in the protease and crystallographic analysis revealed that this down size design was clearly realized without any substantial decrease in potency (Table [1](#bip22773-tbl-0001){ref-type="table"}, entry **3**).

###### 

Data Set of the Properties of an Inhibitor Co‐crystallized With 3CL^pro^

  Compound entry No.   Chemical Structure of Ligand   Complex PDB Code   pIC~50~   Reference
  -------------------- ------------------------------ ------------------ --------- ------------------------------------------
  **1**                                               3AW0               5.244     [8](#bip22773-bib-0008){ref-type="ref"}
  **2**                                               3AVZ               7.187     [8](#bip22773-bib-0008){ref-type="ref"}
  **3**                                               3ATW               7.009     [8](#bip22773-bib-0008){ref-type="ref"}
  **4**                                               4WY3               3.620     [24](#bip22773-bib-0024){ref-type="ref"}
  **5**                                               4TWY               3.967     [24](#bip22773-bib-0024){ref-type="ref"}
  **6**                                               4TWW               4.201     [24](#bip22773-bib-0024){ref-type="ref"}
  **7**                                               5C5O               3.668     This work
  **8**                                               5C5N               3.561     This work
  **9**                --                             3AW1               --        [8](#bip22773-bib-0008){ref-type="ref"}

Based on this wide range surveillance of the surroundings of the active sites by the peptide aldehyde inhibitor, a novel non‐peptide inhibitor based on interactions at the S~1~ and S~2~ sites of SARS 3CL^pro^ was designed and synthesized.[24](#bip22773-bib-0024){ref-type="ref"} In the study, focusing on the fact that P~1~ and P~2~ sites interact with the catalytic dyad and hydrophobic pocket, respectively, compounds were designed by connecting the P~2~ site cyclohexyl group of the substrate‐based inhibitor to the main‐chain at α−nitrogen atom of the P~2~ position Cha via a methylene linker. This strategy gave *aza*‐decaline as a central scaffold of the inhibitor with expected restricted conformational diversity of the P~2~ site. The designed compounds showed substantial inhibitory activity. By X‐ray crystallographic studies (Figure [1](#bip22773-fig-0001){ref-type="fig"}), it was confirmed that the *aza*‐decaline inhibitors were at the active site cleft of 3CL^pro^ and the *aza*‐decaline scaffold was inserted into a large S~2~ pocket, while most of the S~2~ pocket was occupied. Interestingly, the stereochemistry on the *aza*‐decaline scaffold, (4a*S*,8a*R*) and (4a*R*,8a*S*), showed clear differences in inhibitory activities for SARS 3CL^pro^ (Table [1](#bip22773-tbl-0001){ref-type="table"} entries **4**‐**6**). Thus, starting from the substrate mimic peptide aldehyde as a leading compound, we have been developing nonpeptidic inhibitors by extracting fine structure--activity relationships from these crystallographic analyses. However, this stereostructure--activity relationship was not fully evaluated because of a shortage of samples for structural comparison.

![(A) The catalytic site of 3CL^pro^. Six structures containing inhibitors **1**‐**6** were superimposed. The inhibitors are shown in the stick model. The S~2~ pocket is located at approximately the middle position along the direction of depth. The P~3~ and P~4~ of peptide‐based inhibitors **1**‐**3** are extended to the left along with the groove, while *N*‐acyl‐parts of an *aza*‐decaline based inhibitor are directed outward. (B) Schematic drawing of *aza*‐decaline‐based inhibitors **4**‐**8**. The basic structure was divided into three parts. Stereochemistry of positions 4a, 8a, and 3 and the structures of the *N*‐acyl group are different among **4**‐**8**.](BIP-106-391-g001){#bip22773-fig-0001}

The COMparative BINding Energy (COMBINE) method developed by Ortiz[25](#bip22773-bib-0025){ref-type="ref"} is a powerful pipeline for the decomposition of the ligand--receptor interaction energies into a series of terms, extracting latent variables (LV) for the explanation of the interactions and then, assigning weights to selected ligand--residue interactions using multivariate statistics and partial least square (PLS) analysis to correlate with a set of ligand--receptor complexes data on the experimental activities or binding affinities. Gil‐Redondo and colleagues[26](#bip22773-bib-0026){ref-type="ref"} developed gCOMBINE, which is a user‐friendly graphical interface, to perform the analysis with defined input files and sophisticated result presentations. Since the ligand‐induced structural alternation is taken into account, ligand--receptor interactions can be better understood by chemometrical analysis. This method has been applied to various analyses of quantitative structure--activity relationships.[27](#bip22773-bib-0027){ref-type="ref"}, [28](#bip22773-bib-0028){ref-type="ref"}, [29](#bip22773-bib-0029){ref-type="ref"}, [30](#bip22773-bib-0030){ref-type="ref"}, [31](#bip22773-bib-0031){ref-type="ref"}, [32](#bip22773-bib-0032){ref-type="ref"}, [33](#bip22773-bib-0033){ref-type="ref"}, [34](#bip22773-bib-0034){ref-type="ref"}, [35](#bip22773-bib-0035){ref-type="ref"}, [36](#bip22773-bib-0036){ref-type="ref"}, [37](#bip22773-bib-0037){ref-type="ref"}, [38](#bip22773-bib-0038){ref-type="ref"}, [39](#bip22773-bib-0039){ref-type="ref"}, [40](#bip22773-bib-0040){ref-type="ref"}, [41](#bip22773-bib-0041){ref-type="ref"}.

To get further insight into the relations between the configuration of the side chain of the *aza*‐decaline scaffold and the structure of the complexes, we analyzed two new complexes in which the ligands were (4a*S*,8a*R*)‐ and (4a*R*,8a*S*)‐ *aza*‐decaline scaffold. Then, these structures and our previously reported six crystal structures of a complex with a series of ligands and one crystal structure without ligands were collectively referred to derive a quantitative model.

MATERIALS AND METHODS {#bip22773-sec-0002}
=====================

In the present study, two inhibitors were newly synthesized and examined for their inhibitory activity. These inhibitors were complexed with SARS 3CL^pro^ and the complexes were subjected to X‐ray structural analysis. After these structural analyses, another six complex structures containing previously developed inhibitors were subjected to the gCOMBINE, a chemometric analysis. Table [1](#bip22773-tbl-0001){ref-type="table"} shows the chemical structures, PDB IDs, and the properties of the inhibitors.

Synthesis and Determination of Inhibitory Activity of Compounds 7 and 8 {#bip22773-sec-0003}
-----------------------------------------------------------------------

Inhibitors **7** and **8** were synthesized based on the Scheme [1](#bip22773-fig-0009){ref-type="fig"} as previously described with modifications. Briefly, starting from an enantio‐mixture of alcohol **a**, previously reported product[24](#bip22773-bib-0024){ref-type="ref"} by Diels‐Alder reaction, the primary alcohol was converted to azide and then the amino group (**b**). Amine **b** was condensed with *N*‐Boc‐*N*‐phenyl β‐alanine (Ph‐(Boc)bAla) to afford an enantio‐mixture of compound **c**, a precursor of the cyclization reaction. Amide **c**, in which the nitrogen of the amide group located at 5‐carbon apart from olefin, was cyclized with a Pd‐based catalysis.[42](#bip22773-bib-0042){ref-type="ref"} The obtained enantio‐mixture of an *aza‐*decaline derivative, olefin **d** was converted to diol and then to aldehyde by Lemieux‐Johnson oxidation. The resulting *aza*‐decaline‐derived aldehyde and H‐His(Trt)‐N(CH~3~)OCH~3~ were condensed via reductive amination to give a diastereo‐mixture of compound **e**. This diastereo‐mixture was separated and purified by flash column chromatography into **7e** and **8e** corresponding in stereochemistry to **7** and **8**, respectively. Trt and Boc groups of **7e** and **8e** were removed and purified by a silica column. Finally, Weinreb amides were converted to aldehyde and then purified by RP‐HPLC. Yields were 3% and 1% for **7** and **8**, respectively, based on the enantio‐mixture of olefin **d**.

For measurements of IC~50~s of compounds **7** and **8**, peptide substrate, H‐Thr‐Ser‐Ala‐Val‐Leu‐Gln‐Ser‐Gly‐Phe‐Arg‐Lys‐NH~2~, (111 μM) in a reaction solution (25 μL of 20 m*M* Tris‐HCl buffer pH7.5 containing 7 m*M* DTT) was incubated with the R188I SARS 3CL^pro^ (56 nM)[23](#bip22773-bib-0023){ref-type="ref"} at 37°C for 60 min in the presence of various inhibitor concentrations at 37°C for 60 min. The cleavage reaction was monitored by analytical HPLC, a linear gradient of CH~3~CN (10‐20%) in an aq. 0.1% TFA over 30 min, and the cleavage rates were calculated from the decrease in the substrate peak area. Each IC~50~ value was obtained from the sigmoidal dose--response curve. The chemical structure and potency are listed in Table [1](#bip22773-tbl-0001){ref-type="table"}.

Compound **7e**: \[α\]^28^ ~D~ −63.6 (*c* 1.1, CHCl~3~); ^1^H NMR (400 MHz): δ = 7.40‐7.06 (m, 20H), 6.58‐6.55 (s, 2H), 4.71‐4.66 (m, 1H), 4.33‐4.30 (m, 1H), 4.01‐3.82 (m, 4H), 3.60 (s, 2H), 3.53 (s, 1H), 3.09 (s, 3H), 2.81‐2.56 (m, 4H), 2.44‐2.39 (m, 1H), 2.17‐2.11 (m, 1H), 1.75‐1.47 (m, 7H), 1.42 (s, 9H), 1.37‐0.84 (m, 4H); ^13^C NMR (100 MHz): δ = 169.8, 169.2, 154.5, 154.4, 142.51, 142.46, 142.39, 140.3, 138.2, 138.0, 137.7, 137.3, 129.74, 129.71, 128.9, 128.68, 128.64, 128.54, 127.92, 127.90, 127.85, 126.89, 126.85, 125.95, 125.85, 119.3, 119.2, 80.2, 80.1, 77.2, 75.02, 75.0, 61.5, 57.8, 57.5, 53.7, 47.8, 47.3, 47.1, 47.07, 47.04, 46.2, 42.4, 41.7, 36.1, 36.0, 34.2, 32.89, 32.88, 32.6, 32.4, 32.1, 31.9, 29.8, 29.6, 28.3, 26.1, 25.8, 25.7,; HRMS (EI) Calcd. For C~51~H~62~N~6~O~5~ \[M\]^+^: 838.4782. Found: 838.4787.

Compound **8e**: \[α\]^26^ ~D~ −174 (*c* 0.33, CHCl~3~); ^1^H NMR (400 MHz): δ = 7.38‐7.36 (m, 6H), 7.34‐7.25 (m, 9H), 7.20‐7.13 (m, 5H), 7.08‐7.06 (m, 2H), 4.90‐4.62 (m, 1H), 3.87‐3.77 (m, 3H), 3.64‐3.41 (m, 4H), 3.19 (s, 3H), 3.01‐2.30 (m, 7H), 1.73‐1.55 (m, 3H), 1.38 (d, 5.6 Hz, 9H), 1.32‐0.84 (m, 8H); ^13^C NMR (100 MHz): δ = 169.9, 169.4, 154.5, 142.5, 142.4, 138.2, 138.0, 137.5, 137.3, 129.7, 128.7, 128.6, 127.92, 127.89, 127.84, 126.9, 126.8, 125.92, 125.85, 119.2, 80.2, 80.1, 77.2, 75.01, 75.00, 61.5, 58.0, 57.7, 53.9, 42.6, 42.2, 41.7, 36.44, 36.37, 34.45, 33.4, 32.9, 32.6, 32.4, 32.3, 32.2, 29.8, 29.85, 29.80, 29.3, 28.3, 26.14, 26.08, 25.8, 25.7.; HRMS (EI) Calcd. For C~51~H~62~N~6~O~5~ \[M\]^+^: 838.4782. Found: 838.4773.

Compound **7**: (*S*)−2‐\[({(3*S*,4a*R*,8a*S*)−2‐\[3‐(phenylamino)‐propan‐1‐carbonyl\]decahydroisoquinolin‐3‐yl}methyl)amino\]‐3‐(1H‐imidazol‐4‐yl)‐propanal

^1^H NMR (400 MHz): δ = 8.70 (s, 1H), 7.43 (m, 1H), 7.21‐7.17 (m, 2H), 6.80‐6.79 (m, 2H), 5.09 (m, 1H), 4.75‐4.64 (m, 2H), 3.71‐3.61 (m. 1H), 3.50‐3.46 (m, 2H), 3.21‐3.19 (m, 2H), 3.12‐3.12 (m, 2H), 2.91‐2.84 (m, 1H), 2.68‐2.62 (m, 1H), 1.74‐0.91 (m, 12H).; HRMS (EI) Calcd. For C~25~H~33~N~5~O \[M‐H~2~O\]^+^: 419.2685. Found: 419.2689.

Compound **8**: (*S*)−2‐\[({(3*R*,4a*S*,8a*R*)−2‐\[3‐(phenylamino)‐propan‐1‐carbonyl\]decahydroisoquinolin‐3‐yl}methyl)amino\]‐3‐(1H‐imidazol‐4‐yl)‐propanal

^1^H NMR (400 MHz): δ = 8.51 (s, 1H), 7.34‐7.33 (m, 1H), 7.17‐7.12 (m, 2H), 6.73‐6.68 (m, 2H), 5.10 (m, 1H), 4.75‐4.68 (m, 2H), 3.74‐3.51 (m. 1H), 3.48‐3.40 (m, 2H), 3.21‐3.19 (m, 2H), 3.18‐3.14 (m, 2H), 2.90‐2.76 (m, 1H), 2.64‐2.62 (m, 1H), 1.73‐0.91 (m, 12H).; HRMS (EI) Calcd. For C~25~H~33~N~5~O \[M‐H~2~O\]^+^: 419.2685. Found: 419.2682.

X‐Ray Crystallography {#bip22773-sec-0004}
---------------------

The purified SARS 3CL^pro^ in 20 m*M* Bis‐Tris pH5.5, 10 m*M* NaCl, and 1 m*M* DTT was concentrated to 8 mg/mL.[8](#bip22773-bib-0008){ref-type="ref"} Crystals of SARS 3CL^pro^ were grown at 4°C using a sitting‐drop vapor diffusion method by mixing it with an equal volume of reservoir solution containing 100 m*M* MES pH 6.2, 5‐10% PEG20000, and 5 m*M* DTT. Cubic‐shaped crystals with dimensions of 0.3 mm × 0.3 mm × 0.3 mm grew within 3 days. The crystals were then soaked for 24 hours with a reservoir‐based solution of 100 m*M* MES pH 6.2, 5‐8% PEG20000, and 5 m*M* DTT containing 3 m*M* of **7** or **8**. Crystals were then transferred into a cryobuffer of 100 m*M* MES pH 6.2, 10% PEG20000, 5 m*M* DTT, 15% ethylene glycol containing 3 m*M* of **7** or **8**, and flash‐frozen in a nitrogen stream at 100 K. X‐ray diffraction data of SARS 3CL^pro^ in complexes with inhibitor **7** or **8** was collected with a SPring‐8, beamline BL44XU with a Rayonix MX300HE CCD detector at a wavelength of 0.900 Å. The structures of SARS 3CL^pro^ in complex with inhibitors were determined by molecular replacement using the Molrep[43](#bip22773-bib-0043){ref-type="ref"} program with a R188I SARS 3CL^pro^ structure (PDB code 3AW1[8](#bip22773-bib-0008){ref-type="ref"}) as the search model. Rigid body refinement and subsequent restrained refinement protocols were performed with the program Refmac 5[44](#bip22773-bib-0044){ref-type="ref"} of the CCP package.[45](#bip22773-bib-0045){ref-type="ref"} The Coot program[46](#bip22773-bib-0046){ref-type="ref"} was used for manual model rebuilding. Water molecules were added using Coot only after refinement of the protein structures had converged. Ligands generated on JLigand[47](#bip22773-bib-0047){ref-type="ref"} software were directly built into the corresponding difference electron density, and the model was then subjected to an additional round of refinement. The figures of structural representation in this paper were generated on Pymol[48](#bip22773-bib-0048){ref-type="ref"} or UCSF‐Chimera[49](#bip22773-bib-0049){ref-type="ref"} software. Crystallographic data and results of refinement are summarized in Table [2](#bip22773-tbl-0002){ref-type="table"}.

###### 

Data Collection and Refinement Statistics for 3CL^pro^ and Its Inhibitor in Complexes With Compounds 7 and 8

  PDB ID                 5C5O               5C5N
  ---------------------- ------------------ ------------------
  Inhibitor name         **7**              **8**
  Space group            C~121~             P~1~
  Unit cell parameters                      
  Length *a*             107.80             54.66
  Length *b*             82.09              58.66
  Length *c*             53.27              68.10
  Angle *α*              90                 93.73
  Angle *β*              104.35             103.40
  Angle *γ*              90                 106.51
  Resolution             1.65               1.50
  Observations                              
  Unique observations    52746              119208
  Redundancy             4.0                2.2
  Completeness           84.8               95.0
  Mean I/sigma(I)        2.41 (at 1.65 Å)   2.36 (at 1.50 Å)
  *R* ~merge~            0.08               0.06
  Resolution range       37.59--1.69        30.2--1.50
  *R* ~cryst~            0.29               0.25
  *R* ~free~             0.32               0.27
  RMSZ from ideal                           
  Bond length            0.87               0.99
  Bond angle             0.92               1.01

gCOMBINE Analysis {#bip22773-sec-0005}
-----------------

PDB[50](#bip22773-bib-0050){ref-type="ref"} files of the complex (corresponding to PDB ID: 3AW0, 3AVZ, 3ATW, 4TWY, 4TWW, 4WY3, 5C5O and 5C5N)[8](#bip22773-bib-0008){ref-type="ref"}, [24](#bip22773-bib-0024){ref-type="ref"} were prepared as containing a single complex with a ligand. The complexes were imposed on the structure of SARS 3CL^pro^ without a ligand (PDB ID: 3AW1[8](#bip22773-bib-0008){ref-type="ref"}) on the Match‐Maker[51](#bip22773-bib-0051){ref-type="ref"} program based on the main chain Cα of the protease. Each complex was protonated and minimized under an amberFF14SB[52](#bip22773-bib-0052){ref-type="ref"} force field powered by MMTK[53](#bip22773-bib-0053){ref-type="ref"} and inhibitors were assigned AM1‐BCC charges[54](#bip22773-bib-0054){ref-type="ref"} and fully optimized at the AM1 level using the MOPAC program[55](#bip22773-bib-0055){ref-type="ref"} on UCSF‐Chimera.[49](#bip22773-bib-0049){ref-type="ref"} The proteases and inhibitors were saved separately.

The parametrization for the gCOMBINE[26](#bip22773-bib-0026){ref-type="ref"} was performed on the tLEaP module in AMBERTOOL14 program[56](#bip22773-bib-0056){ref-type="ref"} suits. The PDB files of the receptor protease were cleaned by pdb4amber.[57](#bip22773-bib-0057){ref-type="ref"} The antechamber suite[58](#bip22773-bib-0058){ref-type="ref"} has been developed to be used with the general AMBER force field for small molecules. The PDB files of the inhibitor were converted to mol2 files by antechamber, and frcmod and lib files for each inhibitor were generated by parmchk. Each file of the protease and inhibitor was combined and neutrized. For each complex, parameter and topology files were generated.

The COMBINE program was used to decompose the interaction energy between the inhibitor and protein in each complex. That is, this program was used to calculate the Lennard‐Jones and electrostatic interactions between the inhibitor and each protein residue on a per residue basis. gCOMBINE is a graphical interface that runs COMBINE. The gCOMBINE automatically arranges and constructs an **X** matrix in which the rows represent the different compounds studied, and the columns contain the residue‐based energy information, which is separated into two blocks (van der Waals and electrostatic), plus an additional column (**Y** matrix) containing the experimental binding affinities. This **X** matrix was then projected onto a small number of orthogonal LVs using partial least‐squares (PLS) analysis, and the original energy terms were given weights, *w* ~i~, according to their importance in the model, in the form of PLS pseudo coefficients. The higher these coefficients are, the more significant they are for explaining the variance in the experimental data. Thus, in this study, the van der Waals interactions, $u_{i}^{\text{vdw}}$, and the electrostatic interactions, $u_{i}^{\text{ele}}$, between the inhibitor and each protein residue were selected to estimate the pIC~50~ value. The variables that were unimportant for activities were discarded, and the remaining variables were used to build the final PLS model. As a result of COMBINE analysis, gCOMBINE provided a summary of PLS weights, coefficients, rank, and files for PDB with coefficients. In the present study, the PLS ranks were calculated by 5.

RESULTS AND DISCUSSION {#bip22773-sec-0006}
======================

Design, Preparation, and Inhibitory Activities of Inhibitor 7 and 8 {#bip22773-sec-0007}
-------------------------------------------------------------------

The compounds **7** and **8** were designed based on our previous structural analysis of 3CL^pro^ compounds, **1**, **2**, **3**, **4**, **5**, and **6**. Figure [1](#bip22773-fig-0001){ref-type="fig"} shows a summary of our previous structural analysis of the complex with **1**‐**6**. The chemistry of the *aza*‐decaline derived inhibitors including **7** and **8** was divided into three portions: histidine aldehyde (His‐al), *aza*‐decaline, and an *N*‐acyl part (Figure [1](#bip22773-fig-0001){ref-type="fig"}B). The His‐al part took an almost identical conformation and similarly interacted with the 3CL^pro^ over the complexes examined. Briefly, His‐al is located at the active center of 3CL^pro^ as aldehyde and an imidazole ring interacted with the catalytic dyad, thiol of Cys, and imidazole of His, respectively. Thus, the His‐al part functioned as a pharmacophore in these compounds. In contrast, the *N*‐acyl part of the *aza*‐decaline based inhibitors, **4**, **5**, and **6** were directed outward of 3CL^pro^ and then opposite to the P~3~ to P~4~ sites of peptide mimic inhibitors, **1**, **2**, and **3**. Based on these observations, compounds **7** and **8** were designed as making an aromatic ring of the *N*‐acyl part feasible to access the S~3~ or S~4~ pocket of 3CL^pro^ via a relatively flexible β‐alanine linker and are expected to provide greater potency. The stereochemistry of compounds **7** and **8** corresponded to compounds **4** and **5**, respectively.

As for the template for the synthesis of the designed compounds, *aza*‐decaline is an attractive scaffold which is restricted in configuration and can provide distinct and relative positions and directions with substituents. Considering this ability of extension, among the three parts of the basic inhibitor design, an *aza*‐decaline was constructed by two cyclization steps utilizing different chemistries, Diels‐Alder and diastereo‐selective cyclization by PdCl~2~(AcCN)~2~ for cyclohexyl and *aza*‐cyclohexyl on the cyclohexyl, respectively. Since the second cyclization is feasible to react with a wide variety of substrates, the acylation is scheduled in the early steps. On the other hand, since the His‐al part contains a labile group, aldehyde, the reductive amination is scheduled in the late steps. In the present study, the synthetic scheme worked well at least for synthesis of inhibitors **4**‐**8**. Production of a wide variety of inhibitors containing various stereochemistries is to be examined elsewhere based on these key reactions.[42](#bip22773-bib-0042){ref-type="ref"}, [59](#bip22773-bib-0059){ref-type="ref"}, [60](#bip22773-bib-0060){ref-type="ref"}

Although compounds **7** and **8** were designed based on the structural analysis mentioned earlier, the IC~50~s were not improved in comparison with those of the corresponding compounds **4** and **5**, respectively. Compound **7** and **8** inhibited hydrolysis of SARS 3CL^pro^ in IC~50~, 275 μM and 215 μM, respectively.

Structural Analysis of R188I SARS 3CL Protease Complexed with Compounds 7 and 8 {#bip22773-sec-0008}
-------------------------------------------------------------------------------

To investigate the reasons for the deterioration in IC~50~, crystallographic analyses of the SARS 3CL^pro^ in complexes with compounds **7** and **8** were performed. Data collection and refinement statistics for the R188I SARS 3CL protease with compounds **7** and **8** are summarized in Table [2](#bip22773-tbl-0002){ref-type="table"}.

The overall structure of 3CL^pro^ in complex with inhibitors **7** and **8** was similar to the other *aza*‐decaline‐based inhibitors (Figure [2](#bip22773-fig-0002){ref-type="fig"}A). Briefly, the aldehyde group and imidazole ring of His‐al of these inhibitors took an almost identical conformation and similarly interacted with 3CL^pro^. In contrast, the direction of the *aza*‐substituents of the *aza*‐decaline based inhibitors, **7** and **8** (Figure [2](#bip22773-fig-0002){ref-type="fig"}B), were outward from 3CL^pro^ and opposite to the P~3~ to P~4~ sites of peptide mimic inhibitors **1**, **2**, and **3** as in our previous inhibitors, **4**, **5**, and **6** (Figure [1](#bip22773-fig-0001){ref-type="fig"}A). Thus, crystallographic analyses of the SARS 3CL^pro^ in complexes with compounds **7** and **8** revealed that in our case the bAla was not functioning as a flexible linker to reach the Ph group of the hydrophobic S~3~ pocket. These features were in good accordance with the deteriorated IC~50~s of **7** and **8**, which may be due to a higher entropic discordance of **7** and **8** than of **4** and **5**, respectively.

![(A) Interactions of **7** (PDB code 5C5O, left panel) and **8** (PDB code 5C5N, right panel) at the active center of 3CL^pro^. Red and blue meshes represent observed electron density corresponding to 3CL^pro^ and inhibitors, respectively. The inhibitors are shown in the stick model. The S~2~ pocket is located at the top, and the S~1~ pocket at the bottom interact with the *aza*‐decaline and His‐al part of the inhibitor, respectively. (B) The *N*‐acyl‐parts of *aza*‐decaline‐based inhibitors **7** and **8** are directed outward from 3CL^pro^. This figure is the same compositional arrangement as that of Figure 1(A).](BIP-106-391-g002){#bip22773-fig-0002}

The *trans aza*‐decaline scaffolds of **7** and **8** were adapted in the S~2~ pocket as deep as **4** and **5**, respectively. Based on these structural analyses focusing on the chemical structure of the inhibitors, several points to increase potency were revealed. The *aza*‐decaline structure is sufficient to be adapted in the S~2~ pocket, and stereochemistry on the *aza*‐decaline is a determinant for orientation in the S~2~ pocket (Figure [3](#bip22773-fig-0003){ref-type="fig"}). Interestingly, the orientation of *aza*‐decaline in the S~2~ pocket was not critical but was a determinant for relative potency; **4** and **7** were better than **5** and **8**, respectively, in which these scaffolds almost crossed perpendicular to each other when complex structures were superimposed by the whole protein. Thus, the *trans aza*‐decaline scaffold is suitable for embedding into the S~2~ pocket. In comparison with peptide aldehyde inhibitors (Figure [4](#bip22773-fig-0004){ref-type="fig"}), to make the *N*‐acyl‐group of *aza*‐decaline based inhibitors feasible to interact with the S~3~ and S~4~ sites, regioisomers such as 3, 3‐disubstituent or 3, 4‐subtituted *trans aza*‐decaline may be necessary.

![Comparison of the interaction mode of (3*S*,4a*R*,8a*S*)‐ and (3*R*,4a*S*,8a*R*)‐types. The *aza*‐decaline part (3*S*,4a*R*,8a*S*)‐type includes **5**, **6**, and **7** (A) and (3*R*,4a*S*,8a*R*)‐types include **4** and **8** (B). The left and right panels are in the same compositional arrangement in related 3CL^pro^ and are represented as a surface model.](BIP-106-391-g003){#bip22773-fig-0003}

![Comparison of directions of the P~3~ and P~4~ regions of peptide aldehyde inhibitors (A) and the *N*‐acyl‐part of *aza*‐decaline‐based inhibitors (B).](BIP-106-391-g004){#bip22773-fig-0004}

Paasche et al.[61](#bip22773-bib-0061){ref-type="ref"} have pointed out that the low inhibition potencies of known covalently interacting inhibitors may, at least in part, be attributed to insufficient fostering of the proton‐transfer reaction based on MM/MQ analysis of SARS 3CL^pro^. Unfortunately, our method of study was incapable of accessing this charge state. Cleary and colleagues[62](#bip22773-bib-0062){ref-type="ref"} showed that acetal or hemiacetal formation can be one of the components of the inhibitory potency for chymotrypsin. Among the eight complexes used in this study, structural refinements resulted in distances between the carbonyl carbon and sulfide ranging within 1.70--2.54 Å, which included distances judged as chemical bond formation by modeling software. There was, however, no correlation between this distance and potency (*r* = −0.16).

Quantitative Structure--Activity Relationship of R188I SARS 3CL Pro and Inhibitors {#bip22773-sec-0009}
----------------------------------------------------------------------------------

To investigate the structural basis of SARS 3CL^pro^ based on our results, a chemometrical analysis was applied to the crystallographic structures of the complex with inhibitors **1**‐**8**. The ligands, including peptide aldehyde, **1**, **2**, and **3**, which are large enough to cover nonprime sites from P~1~ to P~5~ and two pairs of diasteroisomers of *trans aza*‐decaline **4** and **7** and **5** and **8**, respectively, were expected to give fine structural diversity around the active site. The inputs for the COMBINE program are structural data including topology files, coordination files, and pharmacological activity correlated with ligand binding. In this study, the IC~50~ values were converted to negative logarithmic values, pIC~50~s, which correlated with the binding free energy[63](#bip22773-bib-0063){ref-type="ref"}, [64](#bip22773-bib-0064){ref-type="ref"} of the inhibitors. In Table [1](#bip22773-tbl-0001){ref-type="table"}, values ranging from 3.56 ‐ 7.19 are listed with the inhibitor and the ligand chemical structure.

Based on the input static structures, the program computes residue‐based van der Waals and electrostatic interactions between the residues in each complex and ligand for each complex (Figure [5](#bip22773-fig-0005){ref-type="fig"}). Ligand‐binding pockets from S~1~ to S~4~ were clearly detected. Some of the pockets were located over the structural domains. The figure revealed that S~1~ and S~2~ contribute to inhibitor binding more than other pockets. Extensively, even in the region of S~1~, in which all the examined inhibitors interacted with an identical His aldehyde structure, the calculated energies were not identical. This result illustrates that substitutions can affect fine interactions of the pharmacophore. These energy descriptors for each complex and the corresponding pIC~50~ comprise the **X** and **Y** matrix for the gCOMBINE analysis, respectively. The COMBINE program does PLS analysis such that the composed **X** matrix is then projected onto a small number of orthogonal LVs in an optimized manner for protein--ligand interaction.

![Interactions of 3CL^pro^ and the inhibitor in each complex by residual resolution. Vertical and horizontal axes represent the computed energy of van der Waals (upper graph) and electrostatic (lower graph) interactions and the residue number of 3CL^pro^, respectively. At the top, the schematic drawing of the secondary structure of 3CL^pro^ along with the residue number is presented.](BIP-106-391-g005){#bip22773-fig-0005}

Table [3](#bip22773-tbl-0003){ref-type="table"} shows a chemometric summary of the analysis for the indices of 5 LVs. The optimal dimensionality of the PLS models was determined by monitoring the cross‐validation indexes as a function of the number of LVs extracted. The cross‐validation procedure employed the lease‐one‐out method. The predictive ability of the resulting models was reported by both the cross‐validated correlation coefficient (*q* ^2^) and the standard deviation of error in the predictions. The *q* ^2^ value served as the criterion to determine the optimal dimensionality of the PLS model. Thus, for further analysis, we decided to take ranks by 2 as our model. At this rank, the linear regression analysis reached *r* ^2^ = 0.97 (correlation coefficient). Similar to the primary component analysis, this indicates that the first and second LVs contribute 87% and 10% of the explanation of pIC~50~s in this system, respectively. These results indicate that the first two LVs can explain the pIC~50~s of complexes to a considerable extent.

###### 

Extracted Statistical Summary of Chemometrical Analysis of 3CL^pro^ Complexes

  Numbers of LVs   *r* ^2^     *q* ^2^
  ---------------- ----------- -----------
  1                0.863       0.602
  **2**            **0.971**   **0.632**
  3                0.993       0.577
  4                1.000       0.570
  5                1.000       0.571

The COMBINE program gave several files corresponding to each rank of LV. In fact, for each complex, predicted pIC~50~ by the first two LVs and experimental pIC~50~ were in good correlation and clearly correlated with the corresponding experimental pIC~50~ as shown in Figure [6](#bip22773-fig-0006){ref-type="fig"}. As a consequence, these 8 complexes composed a wide range of pIC~50~s in the order of 3.5.

![Scatter plot comparing experimental vs. predicted activities in COMBINE models for the eight complexes. The two LV model is represented. The straight line is (the diagonal) included in this plot as reference.](BIP-106-391-g006){#bip22773-fig-0006}

**P** matrix (**X**‐loading) in PLS to each LV reflects which and how much residue in a protein is contributing. Figure [7](#bip22773-fig-0007){ref-type="fig"} shows a scatter plot of the part of the residues composing the first and second LVs in the horizontal and vertical axes, respectively. Among these elements which reflect the features of the first two LVs, the top 6 contributing residues for interaction were Pro^168^, Glu^166^, Met^165^, Leu^167^, Tyr^161^, and Gln^192^. On the other hand, Met^49^ prominently contributed a large portion of the second LV.

![Scatter plot of amino acid residues contributing to the LVs. The vertical and horizontal axes correspond to the first and second LVs, respectively. The relevant energy descriptors have been labeled.](BIP-106-391-g007){#bip22773-fig-0007}

For the first LV, residues mainly composing the S~1~ pocket and residues covering a wide range of binding sites were extracted. Thus, the first LV can be interpreted as it stands. Briefly, the first LV for inhibition reflects the fact that the pharmacophore interacts with active site fastening, and parts other than the pharmacophore interact with a wide range of binding sites as seen with peptide mimic inhibitors.

Next, the S~2~ pocket was highlighted in the examining residues related with the second LV. Among these residues, it was revealed that configuration of the dominant Met^49^ is connected to the inhibitory effect of ligand binding. Figure [8](#bip22773-fig-0008){ref-type="fig"}A shows that the active site superimposed on the total 3CL^pro^ structures **1**‐**9**. Structure **9** contains no inhibitor. The catalytic Cys‐His dyads were well overlapped. On the other hand, the configuration of Met^49^ side chains was separated into two groups. In one group, no ligand (**9**), Leu side chain (**1**), and (3*R*,4a*S*,8a*R*) *aza*‐decaline (**4** and **8**) were involved. In the other group, the Cha side chain (**2** and **3**) and (3*S*,4a*R*,8a*S*) *aza*‐decaline (**5**, **6** and **7**) were involved. Inhibitors in the latter group had greater potency in comparison with the corresponding chemical structures. Thus, the S~2~ pocket is enlarged on the potent inhibitors by reorientation of the Met^49^ side chain. Figure [8](#bip22773-fig-0008){ref-type="fig"}B shows the correlation between the **X** score of each complex corresponding to the second LV model and each RMSD of the Met^49^ side chain heavy atom of complexes from that of structure **9**. These values were strongly correlated with *r* = 0.77. Thus, the main contribution to the second LV was the orientation of the Met^49^ side chain followed by enlarging the S~2~ pocket. The isobutyl group of the Leu side chain was not sufficient for inducing this reorientation. Even if a large functional group such as *aza*‐decaline occupied the S~2~ pocket, the angle between the plane consisting of the chair‐chair configuration of *aza*‐decaline and to Met^49^ was critical for the configurational change, which can be controlled by the stereochemistry of position 3 of the *aza*‐decaline scaffold. These analyses revealed that the *aza*‐decaline scaffold with stereochemistry of *S* at position 3 is a novel scaffold for designing an inhibitor to 3CL^pro^. As mentioned in inhibitor‐based analysis, optimized regioisomers need to be elucidated. The key feature of the interaction in the S~2~ pocket gives a novel strategy for developing a new inhibitor.

![(A) Relative occupation and orientation of the catalytic dyad and Met^49^ side chains. Structure of 3CL^pro^ complexes with **1**‐**8** and **9** were superimposed with the whole protein region. The side chains of the three residues are shown in the stick model. (B) Scatter plot showing the correlation between the second LV and orientation of the Met^49^ side chain. The vertical and horizontal axes correspond to the RMSD of Met^49^ from that of structure **9** and the **X** score of LV 2 for each complex.](BIP-106-391-g008){#bip22773-fig-0008}

It is an important and unique strategy in COMBINE that multiple structures are involved in the analysis. This COMBINE strategy may, at least in part, represent the flexibility[65](#bip22773-bib-0065){ref-type="ref"}, [66](#bip22773-bib-0066){ref-type="ref"}, [67](#bip22773-bib-0067){ref-type="ref"} of the protein upon ligand binding. In this research, not protein dynamic structural changes, but configurational change of side chains by inhibitor binding and their substantial control of inhibitory potency were detected. This fact highlights the advantages of the COMBINE method. Together with ligand‐based analysis and the COMIBINE analysis focusing on protein structure, a peptide mimetic inhibitor and development of a small molecular weight molecule is feasible. These sets of training on COMBINE will be adapted to modeled complexes such as docking simulations.

In conclusion, peptidic protease inhibitors were able to increase potency when designed based on structural analysis at each designing step. For *aza*‐decaline based inhibitors, the potencies decreased during design. Structural analysis revealed that orientation of the substituent on the *aza*‐decaline scaffold was not suitable for interacting with the protein. The COMBINE analysis revealed that the volume of the S~2~ pocket perturbed by stereochemistry of the ligand is important for inhibitor potency. This is derived as the second LV (10% explanation of the **X** matrix). Further design and synthesis of inhibitors are expected.

PDB ID Codes of Entry for This Article {#bip22773-sec-0010}
--------------------------------------

5C5O and 5C5N

![Synthesis of inhibitors 7 and 8. Abbreviations: DEAD: diethyl azodicarboxylate, DIBALH: diisobutylaluminum hydride, DIPEA: diisopropylethylamine, HBTU: *O*‐(benzotriazol‐1‐yl)‐*N,N,N′,N′*‐tetramethyluronium hexafluorophosphate, LAH: lithium aluminum hydride, PPh~3~: triphenylphosphine, TFA: trifluoroacetic acid.](BIP-106-391-g009){#bip22773-fig-0009}
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